Clinical Trials Logo

Digestive System Diseases clinical trials

View clinical trials related to Digestive System Diseases.

Filter by:

NCT ID: NCT06321796 Recruiting - Clinical trials for Pitt Hopkins Syndrome

Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders

Start date: February 27, 2024
Phase: Phase 2
Study type: Interventional

The investigators propose to investigate Microbiota Transfer Therapy (MTT) for treating patients with Pitt-Hopkins Syndrome (PTHS) and gastrointestinal problems (constipation, bloating, abdominal pain). MTT involves a combination of 10 days of oral vancomycin (an antibiotic to kill pathogenic bacteria), followed by 1 day of bowel cleanse using magnesium citrate, followed by 4 days of high dose MTP-101P with an antacid, followed by 12 weeks of a lower maintenance dose of MTP-101P with an antacid.

NCT ID: NCT06321614 Active, not recruiting - Clinical trials for Digestive System Disease

Deep Learning in Classifying Bowel Obstruction Radiographs

Start date: December 31, 2022
Phase:
Study type: Observational

Background: Accurate labeling of obstruction site on upright abdominal radiograph is a challenging task. The lack of ground truth leads to poor performance on supervised learning models. To address this issue, self-supervised learning (SSL) is proposed to classify normal, small bowel obstruction (SBO), and large bowel obstruction (LBO) radiographs using a few confirmed samples. Methods: A few number of confirmed and a large number of unlabeled radiographs were categorized based on the ground truth. The SSL model was firstly trained on the unlabeled radiographs, and then fine-tuned on the confirmed radiographs. ResNet50 and VGG16 were used for the embedded base encoders, whose weights and parameters were adjusted during training process. Furthermore, it was tested on an independent dataset, compared with supervised learning models and human interpreters. Finally, the t-SNE and Grad-CAM were used to visualize the model's interpretation.

NCT ID: NCT06314451 Recruiting - Respiratory Disease Clinical Trials

Cross-condition Validation of the Steroid PRO

Start date: June 1, 2022
Phase:
Study type: Observational

Testing a questionnaire about treatment with steroids for skin, lung or gastric conditions

NCT ID: NCT06309199 Not yet recruiting - Clinical trials for Functional Gastrointestinal Disorders

Prevalence of FGIDs and Probiotics Study

PROOF
Start date: March 2024
Phase: N/A
Study type: Interventional

This is a study to evaluate the prevalence of FGIDs in infants using the Thai version of Rome IV diagnostic questionnaire for functional gastrointestinal disorders in infants and evaluate the efficacy of Limosilactobacillus reuteri DSM 17938 to prevent FGIDs in infants.

NCT ID: NCT06301139 Completed - Clinical trials for Gastrointestinal Diseases

Goat Milk Infant Formula Comfort Study

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

In this study, the investigators aim to assess that infants with mild symptoms have significantly less (severe) symptoms after 14 days goat milk-based formula use compared to infants using cow's milk-based formula supplemented with probiotic drops.

NCT ID: NCT06298032 Recruiting - Clinical trials for Inflammatory Gastrointestinal Diseases

A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons

Start date: February 20, 2024
Phase: Phase 1
Study type: Interventional

Interleukin (IL)-6 is a cytokine produced in response to infection and tissue damage. IL-6 is believed to act as a key mediator in chronic inflammation and autoimmune diseases such as inflammatory bowel diseases. IL-6 is known to be involved in at least two distinct signalling pathways, classical and trans-signalling. The hypothesis is that classical signalling by IL-6 infers some beneficial effects (e.g. on gut barrier function), while excessive IL-6 trans-signalling may have detrimental effects. Olamkicept (FE 999301) has been shown in vitro to be a selective IL-6 trans-signalling inhibitor, and administered at lower doses (600 mg every 2nd week for 12 weeks) it has proven to induce clinical improvement for patients with ulcerative colitis. The aim of this trial is to investigate safety, tolerability, immunogenicity and pharmacokinetics of Olamkicept at higher doses (up to 2400 mg) to support the clinical development program. Our hypothesis is that treatment with higher doses of Olamkicept will result in greater clinical improvement for patients with inflammatory bowel diseases.

NCT ID: NCT06290258 Not yet recruiting - Healthy Clinical Trials

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

Start date: March 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate the efficacy of fecal microbiota transplantation on the gastrointestinal symptoms, autistic symptoms and emotional behavior symptoms of patients with autism spectrum disorder, and investigate the relations between the brain-gut axis, cytokines and autism spectrum disorder. Fecal microbiota transplantation have the potentials to improve intestinal microbiota composition, regulate immunity, and then improve gastrointestinal symptoms, autistic symptoms, emotional behavior symptoms and sleep of children with autism spectrum disorder. Early intervention at school-age may even benefit development, improve cognition and prognosis.

NCT ID: NCT06286865 Recruiting - Clinical trials for Gastrointestinal Diseases

Improving Quality of ICD-10 Coding Using AI: Protocol for a Crossover Randomized Controlled Trial

ClinCode
Start date: October 20, 2023
Phase: N/A
Study type: Interventional

The goal of this randomised trial is to learn about the role of AI in clinical coding practice. The main question it aims to answer is: Can the AI-based CAC system reduce the burden of clinical coding and also improve the quality of such coding? Participants will be asked to code clinical texts both while they use our CAC system and while they do not.

NCT ID: NCT06283732 Completed - Clinical trials for Digestive System Disease

A Clinical Study to Assess the Effect of a Supplement on Digestive Health, Overall Well-being, and Participant Experience.

Start date: November 15, 2023
Phase: N/A
Study type: Interventional

The study aims to evaluate the effectiveness of a dietary supplement (greens powder), on improving digestive health, quality of life, energy levels, and satiety over a 14-day period. Participants, aged 18-65 and experiencing mild digestive issues, will consume the greens powder daily and report outcomes through diaries and questionnaires.

NCT ID: NCT06279546 Completed - Clinical trials for Gastrointestinal Diseases

Artificial Intelligence vs Endoscopist Identification in EUS Normal Anatomy

Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

Endoscopic ultrasound (EUS) visual impression is operator-dependant and can hinder diagnostic accuracy, especially in less experienced endoscopists. The implementation of artificial intelligence can potentially mitigate operator dependency and interpretation variability, helping or improving the overall accuracy. The investigators therefore aim to compare diagnostic accuracy between artificial intelligence (AI)-based model and the endoscopists when identifying normal anatomical structures in EUS-procedures.